author-photo

Enrico Repetto

AstraZeneca

7

Papers

57

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Benefit:Risk Profile of Dapagliflozin 5 mg in the DEPICT-1 and -2 Trials in Individuals with Type 1 Diabetes and BMI ≥27 kg/m2.

2020 Diabetes, Obesity and Metabolism
Show All
- Source
- Cite
- Save
Citations (5)
Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials.

2020 The Lancet Diabetes & Endocrinology
Show All
- Source
- Cite
- Save
Citations (12)
Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus

2019 American Journal of Nephrology
Show All
- Source
- Cite
- Save
Citations (12)
SUN-142 High Prevalence of NAFLD and Advanced Fibrosis in Patients with Obesity and Diabetes

2019 Journal of the Endocrine Society
Show All
- Source
- Cite
- Save
Citations (0)